An integrase inhibitor fared well in a head-to-head comparison with a protease inhibitor regimen for people just starting ART. Find out why this is surprising and what it could mean for treatment naïve people with high viral loads. Read More
Placing HIV and hepatitis C drugs on “specialty” tiers affects their access and affordability. Supervisor Scott Wiener called attention to this issue during a recent San Francisco hearing.
Recent drug advances bring a cure for hepatitis C to many. But delayed treatment, liver disease, and drug costs all give cause for concern. Read More
A new type of drug has been found to help reduce the viral reservoir by “shocking” HIV-infected cells out of latency and making them more susceptible to a killing mechanism.
Dr. Paul Volberding played an integral role in establishing a dedicated HIV/AIDS treatment program at San Francisco General in 1983. The San Francisco Examiner recently published a piece sharing his perspective on how far we’ve come since the early days of the epidemic. Read More